Marshall Wace’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Marshall Wace’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-320,517	Closed	-$3.29M	–	2872
2023 Q2	$3.29M	Hold	320,517	–	–	0.01%	1195
2023 Q1	$3.24M	Sell	320,517 -576,422	-64%	-$5.81M	0.01%	1206
2022 Q4	$8.97M	Hold	896,939	–	–	0.02%	864
2022 Q3	$8.73M	Hold	896,939	–	–	0.02%	979
2022 Q2	$8.69M	Hold	896,939	–	–	0.02%	958
2022 Q1	$8.75M	Buy	896,939 +492,500	+122%	+$4.76M	0.02%	968
2021 Q4	$3.97M	Buy	404,439 +4,439	+1%	+$43.5K	0.01%	1545
2021 Q3	$3.93M	Buy	+400,000	New	+$3.95M	0.02%	1087

Marshall Wace's DALS Position: Q3 2023 in Review

Marshall Wace sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 320,517 shares — an estimated $3.29M sold.

Marshall Wace first reported a position in DALS in Q3 2021 and held it in 8 quarters. The position peaked at $8.97M in Q4 2022. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Marshall Wace reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Marshall Wace sold 320,517 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $3.29M.
Marshall Wace first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 8 quarters.
Marshall Wace's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $8.97M in Q4 2022.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.